Alternative Immunomodulatory and Disease-Modifying Treatment for Atopic Dermatitis: Autologous Total Immunoglobulin G by 박창욱
903https://e-aair.org
Atopic dermatitis (AD) is a chronic relapsing eczematous cutaneous disease whose 
incidence is rapidly increasing worldwide.1 In the recent few decades, tremendous advances 
in cutaneous immunology have detailed documentation on the pathophysiology of AD. 
Understanding of immune cell functions and interactions of cytokines with AD have 
helped discover various therapeutic target molecules. Especially, dupilumab, which binds 
to interleukin (IL)-4 receptors and interferes with Th2-immune responses, has shown their 
efficacy and lower rate of adverse events in clinical trials as well as real clinical settings.2,3 
Nevertheless, AD treatment has not been completely successful. There are some patients who 
do not respond well to dupilumab; especially in Korea, even though the cost for biologics is 
very high, very few patients can be covered by an insurance because strict conditions have to 
be fulfilled. In addition, it has not yet been determined whether the efficacy of dupilumab 
continues even after cessation of injection. In this circumstance, the most frequently asked 
question from patients benefit from dupilumab therapy is whether they should receive 
dupilumab injections for a lifetime. Therefore, many studies are being conducted to find out 
the alternative treatment modalities which can assist in traditional treatments or biologics.
In the current issue of the Allergy, Asthma & Immunology Research, Nahm et al.4 assessed the 
efficacy, safety and immunomodulatory effects of intramuscular autologous immunoglobulin 
G injection (AIGT) for AD. Before this research, the authors consistently reported the efficacy 
of AIGT in AD for years. In 2015, the authors first demonstrated the efficacy of AIGT, which was 
a pilot study of 17 adult patients with severe AD.5 In that study, AIGT given twice a week for 4 
weeks significantly decreased clinical severity and serum immunoglobulin (Ig) E concentration 
in all 17 patients. In addition, clinical and laboratory improvements by AIGT lasted for 8 weeks 
even after its cessation. After publication of that pilot study, the authors proceeded to a 2-year 
long-term follow-up of 3 severe AD patients with the same protocol for AIGT,6 which showed 
the possible residual effect of AIGT for about 1 year. For the immunologic mechanisms of 
AIGT, the authors attempted to define immunomodulatory effects of AIGT using objective 
measurements of serum Ig levels, including IgE, IgG, and IgG4 and serum cytokine levels, 
including IL-10, IL-4, IL-12, and interferon (IFN)-γ.7 In that study, a decrease in IgE and an 
increase in IgG and IgG4 (especially for Dermatophagoides farinae) were noted. Also, the authors 
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inferred that the main immunomodulatory effect of AIGT might be achieved through regulatory 
T-cell response which was suggested by the increased levels of IL-10 and IFN-γ. However, those 
studies were neither randomized nor double-blinded, and the number of subjects was too small 
to confirm sure the efficacy and safety of AIGT.
Based on those studies, Nahm et al.4 conducted the randomized, double-blind, well-fashioned 
clinical trials with AIGT. After 7 weeks of overall 8 injections of autologous IgG, a significant 
improvement in clinical severity (e.g. EASI and SCORAD) was noted. Also, the study showed 
that there might be a residual effect of AIGT. The study was conducted using a single center-
based protocol. Thus, large-scale, multi-center, randomized, clinical trials would be needed 
to confirm the exact efficacy and safety, including the residual effects of AIGT for AD. Also, 
comparisons between autologous IgG and commercially available IgG could be one needed to 
explore whether the clinical efficacy proposed by the authors is attributed to the ‘autologous’ 
nature of AIGT.
The authors showed that intramuscular AIGT might exert their efficacy via modulation of 
regulatory T-cell functions, which was inferred from increased IL-10 and IFN-γ-producing T 
cells in AD patients.4 However, detailed mechanisms how the IgG provokes regulatory T-cell 
responses are still unclear. In a study, the authors suggested that the idiotype network theory 
might be one of the underlying mechanisms of AIGT. The idiotype network theory proposes 
idiotype-anti-idioytpe immune responses, which not only induce immune tolerance in 
humans, but also actively suppress pathological immune responses.8,9 Although this theory 
might be one of the explanations of the mechanism of action of AIGT, there still remains a 
big gap between AIGT and regulatory T-cell responses. For example, IgG is known to interact 
with various immune cells via cellular Fcγ-receptors (FcγR). In humans, there are 3 kinds of 
activating FcγR (Ia, IIa and IIIa) and 1 inhibitory FcγR (IIb). According to previous studies 
on autoimmune disease, IFN-γ or tumor necrosis factor-α can alter the expression ratio of 
activating to inhibitory FcγR, so that the thresholds for provoking immune responses can be 
modulated in immune cells.10 Therefore, it is conceivable that the interaction between IgG 
and FcγR on immune cells can be another plausible explanation. In this way, there are many 
theories to explain the efficacy of AIGT in AD patients.
In conclusion, effective biologics are currently used even in real-world settings, although 
clinical efficacy is still insufficient to satisfy all AD patients with various immunologic, 
clinical phenotypes.11 Also, moderate to severe AD patients might suffer from the high cost 
of these new targeted antibodies, which is being a constant stumbling block to AD patients 
who are willing to, even ought to benefit from emerging advancement in understanding the 
pathophysiology of AD.12 In this circumstance, long-term effects of AIGT which are shown 
by Nahm et al.4 might lead to the cost-effective, safe alternative treatment modality in AD, or 
even the mainstay of AD treatment. Thus, these AD-modifying treatment strategies for AD 
could be widely used, evidence-based treatment modalities if its underlying immunologic 
mechanisms is clearly elucidated with further studies.
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